Global perspective. Clear attribution. Updated throughout the day.
Live desk Concise briefs from trusted publishers · Always follow the source for the full report
Markets
GBP/USD 1.3383 FrankfurterEUR/USD 1.1482 FrankfurterUSD/NGN 1,328.85 FrankfurterUSD/JPY 157.39 FrankfurterGold $4,338.00/oz Gold APISilver $66.64/oz Gold API
Breaking
Madagascar say they will not be intimidated by Nigeria Punch NigeriaNigeria’s 23-man squad starts Uyo training before Madagascar qualifier Punch NigeriaAdepoju says Nigeria can cope with Osimhen’s absence Punch NigeriaKayode says representing Italy was an easy choice after youth-team pathway Punch NigeriaAmedspor says Orban needs three more goals for permanent transfer Punch NigeriaIIT-B professor sent on leave as Crime Branch prepares to question him India TodayTurkish pundit calls Onuachu a top scorer despite current poor form Punch NigeriaMoyes reportedly set to assess Alebiosu in Blackburn friendly Punch NigeriaOsimhen expected to return for Galatasaray after break Punch NigeriaXi’s special plane draws comparisons with Air Force One South China Morning Post
Scores
Birmingham Legion v Brooklyn FC 16:00 UTC American USL Championship · TheSportsDBIndependiente Santa Fe v Deportivo Cali 0–1 Colombia Categoría Primera A · TheSportsDBADT v Cienciano 20:00 UTC Peruvian Primera Division · TheSportsDB
Science & Health

Pfizer stresses patient safety during Karnataka investigation into fake drugs

Source: NDTV · 23 Sep 2026, 01:52 UTC

Pfizer said patient safety remains its top priority as authorities investigate fake drugs in Karnataka. The company said it was working closely with officials to resolve outstanding questions and highlighted public-health protection and confidence in the healthcare system. The supplied material does not identify the medicines involved or describe the investigation’s findings.

Pfizer said it was working closely with authorities during an investigation into fake drugs in Karnataka. The company said it continued to cooperate in resolving outstanding questions linked to the probe. Pfizer emphasised that its focus was protecting patients, safeguarding public health and maintaining confidence in the healthcare system.

The supplied material does not specify which products are under examination, how many medicines may be affected, or what authorities have concluded. It also does not provide details of any regulatory or legal action.

About this report
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.
View the original source at NDTV →